A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

Inclusion Criteria

• •1. Male or female ≥ 18 years of age.
• •2. Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria (excluding the "more than one affected relative" criterion).
• •3. Clinically meaningful response to Levodopa (L-Dopa) with well-defined "OFF" episodes, as determined by the Investigator.
• •4. Receiving APOKYN® of ≤ 5 mg per dose for at least 4 weeks before the Screening Visit.
• •5. Receiving stable doses of L-Dopa/carbidopa (immediate or sustained release) administered at least 4 times per day OR Rytary™ administered 3 times per day, for at least 4 weeks before the Screening Visit. Adjunctive PD medication regimens must be maintained at a stable dose for at least 4 weeks prior to the Screening Visit with the exception that MAOB inhibitors must be maintained at a stable level for at least 8 weeks prior to the Screening Visit.
• •6. No planned medication change(s) or surgical intervention anticipated during the course of study.
• •7. Patients must experience a well-defined "OFF" episode in the morning if they do not take their morning PD medications on schedule, and must be willing to delay morning doses on the 3 study dosing days
• •8. Stage III or less on the modified Hoehn and Yahr scale in the "ON" state.
• •9. Mini-Mental State Examination (MMSE) score \> 23.
• •10. If female and of childbearing potential, must agree to use one of the following methods of birth control:
• •* Oral contraceptive;
• •* Contraceptive patch;
• •* Barrier (diaphragm, sponge or condom) plus spermicidal preparations;
• •* Intrauterine contraceptive system;
• •* Levonorgestrel implant;
• •* Medroxyprogesterone acetate contraceptive injection;
• •* Complete abstinence from sexual intercourse;
• •* Hormonal vaginal contraceptive ring; or
• •* Surgical sterilization or partner sterile (must have documented proof).
• •11. Male patients must be either surgically sterile, agree to be sexually abstinent or use a barrier method of birth control (e.g., condom) or maintain a monogamous relationship with a person who is not of child-bearing potential from first study drug administration until 30days after final drug administration.
• •12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
• •13. Able to understand the consent form, and to provide written informed consent